Optimind Pharma Corp.
OMND
CNSX
| 05/31/2025 | 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 115.25% | 17.48% | -1.03% | 46.34% | -61.18% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 115.25% | 17.48% | -1.03% | 46.34% | -61.18% |
| Cost of Revenue | -14.77% | 405.56% | -18.56% | -41.07% | -54.87% |
| Gross Profit | 496.67% | -19.68% | 16.33% | 428.95% | -72.73% |
| SG&A Expenses | -76.82% | -74.56% | -78.13% | -30.66% | -62.11% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -70.13% | -67.44% | -72.62% | -34.88% | -73.28% |
| Operating Income | 101.43% | 84.81% | 92.88% | 49.65% | 74.62% |
| Income Before Tax | 99.72% | 96.48% | 91.37% | 56.21% | 75.97% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 99.72% | 96.44% | 91.37% | 56.21% | 75.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 99.72% | 96.44% | 91.37% | 56.21% | 75.97% |
| EBIT | 101.43% | 84.81% | 92.88% | 49.65% | 74.62% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 100.00% | 96.08% | 87.50% | 57.14% | 80.00% |
| Normalized Basic EPS | 100.00% | 93.33% | 100.00% | 66.67% | 78.95% |
| EPS Diluted | 100.00% | 96.08% | 87.50% | 57.14% | 80.00% |
| Normalized Diluted EPS | 100.00% | 93.33% | 100.00% | 66.67% | 78.95% |
| Average Basic Shares Outstanding | -10.42% | 5.69% | 11.92% | 11.40% | 19.32% |
| Average Diluted Shares Outstanding | -10.42% | 5.69% | 11.92% | 11.40% | 19.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |